Literature DB >> 24614378

A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureus.

Katie E Barber1, Brian J Werth, John P McRoberts, Michael J Rybak.   

Abstract

Medical device infections frequently require combination therapy. Beta-lactams combined with glycopeptides/lipopeptides are bactericidal against methicillin-resistant Staphylococcus aureus (MRSA). Novel macrowell kill-curve methods tested synergy between ceftaroline or cefazolin plus daptomycin, vancomycin, or rifampin against biofilm-producing MRSA. Ceftaroline combinations demonstrated the most pronounced bacterial reductions. Ceftaroline demonstrated greatest kill with daptomycin (4.02 ± 0.59 log10 CFU/cm(2)), compared to combination with vancomycin (3.36 ± 0.35 log10 CFU/cm(2)) or rifampin (2.68 ± 0.61 log10 CFU/cm(2)). These data suggest that beta-lactam combinations are useful against MRSA biofilms.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24614378      PMCID： PMC3993275          DOI： 10.1128/AAC.02764-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

Review 1.  Biofilms and antimicrobial resistance.

Authors:  Robin Patel
Journal:  Clin Orthop Relat Res       Date:  2005-08       Impact factor: 4.176

Review 2.  Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides.

Authors:  Suzana K Straus; Robert E W Hancock
Journal:  Biochim Biophys Acta       Date:  2006-03-03

Review 3.  Bacterial and fungal biofilm infections.

Authors:  A Simon Lynch; Gregory T Robertson
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

4.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.

Authors:  Leonard A Mermel; Michael Allon; Emilio Bouza; Donald E Craven; Patricia Flynn; Naomi P O'Grady; Issam I Raad; Bart J A Rijnders; Robert J Sherertz; David K Warren
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079

5.  Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Douglas R Osmon; Elie F Berbari; Anthony R Berendt; Daniel Lew; Werner Zimmerli; James M Steckelberg; Nalini Rao; Arlen Hanssen; Walter R Wilson
Journal:  Clin Infect Dis       Date:  2012-12-06       Impact factor: 9.079

6.  In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.

Authors:  Kristi L Frank; Emily J Reichert; Kerryl E Piper; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2006-12-11       Impact factor: 5.191

7.  Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.

Authors:  Jorge Parra-Ruiz; Celine Vidaillac; Warren E Rose; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-08-09       Impact factor: 5.191

8.  Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

Authors:  Dawn M Sievert; Philip Ricks; Jonathan R Edwards; Amy Schneider; Jean Patel; Arjun Srinivasan; Alex Kallen; Brandi Limbago; Scott Fridkin
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-27       Impact factor: 3.254

Review 9.  Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature.

Authors:  Joshua Perlroth; Melissa Kuo; Jennifer Tan; Arnold S Bayer; Loren G Miller
Journal:  Arch Intern Med       Date:  2008-04-28

10.  In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model.

Authors:  Céline Vidaillac; Steve N Leonard; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191
View more
  13 in total

1.  Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Biofilm Model.

Authors:  Seyedehameneh Jahanbakhsh; Nivedita B Singh; Juwon Yim; Warren E Rose; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

2.  Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.

Authors:  Katie E Barber; Jordan R Smith; Cortney E Ireland; Blaise R Boles; Warren E Rose; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2015-05-18       Impact factor: 5.191

3.  Evaluation of Oritavancin Combinations with Rifampin, Gentamicin, or Linezolid against Prosthetic Joint Infection-Associated Methicillin-Resistant Staphylococcus aureus Biofilms by Time-Kill Assays.

Authors:  Qun Yan; Melissa J Karau; Yash S Raval; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

4.  Adjuvant antibiotic-loaded bone cement: Concerns with current use and research to make it work.

Authors:  Edward M Schwarz; Alex C McLaren; Thomas P Sculco; Barry Brause; Mathias Bostrom; Stephen L Kates; Javad Parvizi; Volker Alt; William V Arnold; Alberto Carli; Antonia F Chen; Hyonmin Choe; Débora C Coraça-Huber; Michael Cross; Michelle Ghert; Noreen Hickok; Jessica Amber Jennings; Manjari Joshi; Willem-Jan Metsemakers; Mark Ninomiya; Kohei Nishitani; Irvin Oh; Douglas Padgett; Benjamin Ricciardi; Kordo Saeed; Parham Sendi; Bryan Springer; Paul Stoodley; Joseph C Wenke
Journal:  J Orthop Res       Date:  2020-03-02       Impact factor: 3.102

5.  Role of daptomycin in the induction and persistence of the viable but non-culturable state of Staphylococcus aureus biofilms.

Authors:  Sonia Pasquaroli; Barbara Citterio; Andrea Di Cesare; Mehdi Amiri; Anita Manti; Claudia Vuotto; Francesca Biavasco
Journal:  Pathogens       Date:  2014-09-18

6.  Induction heating for eradicating Staphylococcus epidermidis from biofilm.

Authors:  Bart G Pijls; Ingrid M J G Sanders; Ed J Kujiper; Rob G H H Nelissen
Journal:  Bone Joint Res       Date:  2020-05-16       Impact factor: 5.853

Review 7.  Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance.

Authors:  Kushal Vanamala; Katyayani Tatiparti; Ketki Bhise; Samaresh Sau; Marc H Scheetz; Michael J Rybak; David Andes; Arun K Iyer
Journal:  Drug Discov Today       Date:  2020-10-20       Impact factor: 7.851

8.  Effects of Subinhibitory Concentrations of Ceftaroline on Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms.

Authors:  María Lázaro-Díez; Sara Remuzgo-Martínez; Cristina Rodríguez-Mirones; Felix Acosta; Jose M Icardo; Luis Martínez-Martínez; José Ramos-Vivas
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

9.  Susceptibility patterns of Staphylococcus aureus biofilms in diabetic foot infections.

Authors:  Carla Mottola; Carina S Matias; João J Mendes; José Melo-Cristino; Luís Tavares; Patrícia Cavaco-Silva; Manuela Oliveira
Journal:  BMC Microbiol       Date:  2016-06-23       Impact factor: 3.605

10.  Decreased rate of surgical site infection after spinal surgery with instrumentation using bundled approach including surveillance and intrawound vancomycin application.

Authors:  Takashi Sono; Shunsuke Fujibayashi; Masanori Izeki; Yu Shimizu; Kazutaka Masamoto; Kazuaki Morizane; Bungo Otsuki; Shimei Tanida; Miki Nagao; Satoshi Ichiyama; Shuichi Matsuda
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.